Kim Yeo-Gab, Lee Baek-Soo, Kwon Yong-Dae Study on bisphosphonate-related osteonecrosis of the jaw (BRONJ): case report and literature review. J Korean Assoc Oral Maxillofac Surg. 2010; 36:291-302
Ruggiero SL. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Min Bone Metab. 2007; 4:37-42
Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol: Cancer Clinical Trials. 2012; 35:386-392
Adamo V, Caristi N, Sacca M Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Exp Opin Pharmaco. 2008; 9:1351-1361
Arrain Y, Masud T. Recent recommendations on bisphosphonate associated osteonecrosis of the jaw. Dent Update. 2008; 35:238-242
Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc. 2006; 137:1115-1119
The characteristics of bisphosphonate patients developing bisphosphonate-related osteonecrosis of the jaw attending an OMFS department Paul S Serrant Stuart Clark Dental Update 2024 40:9, 707-709.
Authors
Paul SSerrant
MFDS RCS(Ed), MJDF RCS(Eng)
SHO Oral and Maxillofacial Surgery, Wigan Royal Albert Edward Infirmary, Wigan, Lancashire WN1 2NN, UK
This case series considers the incidence of patients taking bisphosphonate medication that suffer with bisphosphonate-related osteonecrosis of the jaw (BRONJ) following an exodontia procedure. Forty five such patients who attended the Wigan Royal Albert Edward Infirmary (RAEI) Oral and Maxillofacial Surgery (OMFS) department for an exodontia procedure were examined. A patient's age, gender, exodontia technique, bisphosphonate route (Oral/IV), smoking status and reason for taking the bisphosphonates, eg osteoporosis/cancer/arthritis was considered. All of the patients that experienced BRONJ were smokers.
Clinical Relevance: Bisphosphonates are now widely accepted for the management of medical conditions, including arthritis, osteoporosis and various forms of cancer. Such patients are regularly referred to OMFS departments for dental extractions.
Article
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a recognized side-effect of bisphosphonate use.1 Oral bisphosphonates may be prescribed to treat conditions such as arthritis/osteoporosis and intravenous (IV) bisphosphonates are now widely used in the treatment of various forms of cancer, eg breast and prostate cancers. Such patients are regularly referred to the OMFS department for dental extractions. This case study aims to give an insight into the risk factors for the development of BRONJ that affect patients taking oral and IV bisphosphonate medication following dental extraction.
Patients were considered to have BRONJ if all of the following three characteristics are present:2
The clinical records of 45 patients, who were taking bisphosphonate medication and attended the Wigan Royal Infirmary OMFS department for dental extractions between 1/8/2011 and 1/08/2012, were examined. The following data were recorded:
Antibiotic prophylaxis (Co-Amoxiclav 625 mg) was used pre/post-operatively for all patients considered to be at risk of developing BRONJ. Lidocaine-adrenaline 1:80 000 was the local anaesthetic of choice for all dental extraction procedures undertaken on this group of patients. Patients that had undergone radiotherapy to the head and neck area and diabetic patients were excluded.
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
